Cystic Fibrosis Market Outlook to 2022 - Global Strategic Business Report 2018 Featuring 56 Key & Niche Company Profiles - ResearchAndMarkets.com

July 4, 2018

DUBLIN--(BUSINESS WIRE)--Jul 4, 2018--The “Cystic Fibrosis - Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.

The report provides separate comprehensive analytics for the US, Canada, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2022.

This report analyzes the worldwide markets for Cystic Fibrosis in US$ Million.

The report profiles 56 companies including many key and niche players such as:

Advanced Inhalation Therapies (AIT) Ltd (Israel) Alaxia SAS (France) AlgiPharma AS (Norway) Anthera Pharmaceuticals, Inc. (USA) Arch BioPartners (Canada) Celtaxsys, Inc. (USA) Concert Pharmaceuticals, Inc. (USA) Corbus Pharmaceuticals Holdings, Inc.(USA) CURx Pharmaceuticals (USA) Nivalis Therapeutics, Inc. (USA) NovaBiotics Ltd (UK) Parion Sciences, Inc. (USA) Pharmaxis Ltd (Australia) PTC Therapeutics, Inc. (USA) Pulmatrix, Inc. (USA)

Key Topics Covered

1. Market Overview

2. Research in Cystic Fibrosis Space

3. Disease Overview

4. Cystic Fibrosis Treatment: An Overview

5. Clinical Studies

6. Product Launches/Approvals

7. Recent Industry Activity

8. Select Clinical-Stage Players

9. Focus on Select Global Players

Total Companies Profiled: 56 (including Divisions/Subsidiaries 58)

The United States (30) Canada (4) Europe (20) France (2)Germany (2)The United Kingdom (3)Italy (2)Rest of Europe (11) Asia-Pacific (Excluding Japan) (1) Middle East (3)

For more information about this report visit https://www.researchandmarkets.com/research/qdr9gs/cystic_fibrosis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180704005173/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs,Pulmonary Medicine



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/04/2018 09:39 AM/DISC: 07/04/2018 09:39 AM


Update hourly